argenx (ARGX) Competitors

BioNTech (NASDAQ:BNTX) and argenx (NASDAQ:ARGX) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, community ranking, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

Does the MarketBeat Community prefer BNTX or ARGX?

argenx received 463 more outperform votes than BioNTech when rated by MarketBeat users. Likewise, 66.20% of users gave argenx an outperform vote while only 41.56% of users gave BioNTech an outperform vote.

Company	Underperform	Outperform
BioNTech	Outperform Votes 101 41.56%	Underperform Votes 142 58.44%
argenx	Outperform Votes 564 66.20%	Underperform Votes 288 33.80%

Does the media refer more to BNTX or ARGX?

In the previous week, BioNTech had 4 more articles in the media than argenx. MarketBeat recorded 13 mentions for BioNTech and 9 mentions for argenx. argenx's average media sentiment score of 0.74 beat BioNTech's score of 0.39 indicating that argenx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	4 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
argenx	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk & volatility, BNTX or ARGX?

BioNTech has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500. Comparatively, argenx has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500.

Do institutionals and insiders believe in BNTX or ARGX?

15.3% of BioNTech shares are held by institutional investors. Comparatively, 57.3% of argenx shares are held by institutional investors. 19.2% of BioNTech shares are held by company insiders. Comparatively, 2.4% of argenx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Do analysts recommend BNTX or ARGX?

BioNTech presently has a consensus price target of $171.07, suggesting a potential upside of 58.20%. argenx has a consensus price target of $455.67, suggesting a potential upside of 15.13%. Given BioNTech's higher probable upside, equities analysts clearly believe BioNTech is more favorable than argenx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	0 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.46
argenx	0 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.95

Is BNTX or ARGX more profitable?

BioNTech has a net margin of 51.03% compared to argenx's net margin of -79.45%. BioNTech's return on equity of 32.52% beat argenx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	51.03%	32.52%	27.56%
argenx	-79.45%	-35.36%	-32.04%

Which has higher earnings and valuation, BNTX or ARGX?

BioNTech has higher revenue and earnings than argenx. argenx is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$12.21 billion	2.15	$9.94 billion	$26.01	4.16
argenx	$445.27 million	49.49	-$709.59 million	-$9.29	-42.60

Summary

BioNTech beats argenx on 10 of the 18 factors compared between the two stocks.